Korro Bio, Inc.
korrobio.comWhat Do They Do?
Develops RNA-editing genetic medicines, including oligonucleotide therapies designed to repair or alter proteins, for people with rare and common diseases.
10-K for FY2025, filed Mar 12, 2026We are a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing…View ↗
As opposed to gene silencing with small interfering RNA, or siRNA, or antisense oligonucleotide, or ASO, gapmers, where oligonucleotides…View ↗
The pipeline chart below demonstrates the breadth of indications, with an initial focus on four wholly-owned programs:View ↗
How Do They Make Money?
Has not generated product-sales revenue; collaboration revenue comes from research collaboration and licensing arrangements. For a distinct license, payment is tied to the license transfer, while collaboration services may be paid for as work is completed; sales-based royalties are tied to related sales.
10-K for FY2025, filed Mar 12, 2026We do not have any development candidates approved for sale and have not generated any revenue from product sales. We will not generate…View ↗
We have not generated any revenue from product sales, and do not expect to generate any revenue from the sale of products in the near…View ↗
The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the…View ↗
Licenses of intellectual property, or IP: If the license to the Company’s IP is determined to be distinct from the other performance…View ↗
Commercial milestone payments and royalties: For arrangements that include sales-based royalties, including milestone payments based on…View ↗
$6.4M
-
10-K for FY2025, filed Mar 12, 2026
$6.4M ↗
Who Are Their Customers?
Its research and licensing collaborator Novo Nordisk pays for collaboration work and licenses under a research collaboration and license agreement.
10-K for FY2025, filed Mar 12, 2026
Do Revenues Turn Into Profits?
No. It lost $117.3M in FY2025.
10-K for FY2025, filed Mar 12, 2026
−$121.9MView ↗
10-K for FY2025, filed Mar 12, 2026
−$117.3MView ↗
10-K for FY2025, filed Mar 12, 2026
−$79.1MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$18.9MView ↗
- ▼ −27% (Loss)
- vs −$25.8M in Q2 FY2025
-
Aug 19, 2026
Submitted application to start KRRO-121 first-in-human trial
The submission seeks to initiate a Phase 1/2 trial in healthy volunteers and participants with urea cycle disorders.
Sources
8-K, filed Aug 19, 2026
On August 19, 2026, Korro Bio, Inc., or Korro, announced a submission to the Australian Alfred Health Human Ethics Committee to initiate a…View ↗
-
Aug 6, 2026
Selected KRRO-111 as an AATD development candidate
The program is designed to repair AAT RNA using a subcutaneous oligonucleotide.
Sources
8-K, filed Aug 6, 2026
Nominated KRRO-111 as development candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD); potential best-in-class therapeutic…View ↗
Shrinking. Revenue fell 55% in 4 years, from $14.1M in FY2021 to $6.4M in FY2025, about 18% a year.
From regenerative medicines to RNA editing
The older report described small-molecule therapies that activate progenitor cells, with a focus on remyelination for multiple sclerosis. The latest report describes oligonucleotide medicines that edit RNA to repair or alter proteins across rare and common diseases.
10-K for FY2022, filed Mar 10, 2023 10-K for FY2025, filed Mar 12, 2026
Who Do They Compete With?
Competes with AIRNA, Beam Therapeutics, Prime Medicine, ProQR, Tessera Therapeutics, Verve Therapeutics, Wave Life Sciences, YolTech Therapeutics, Edigene, and Shape Therapeutics
10-K for FY2025, filed Mar 12, 2026The pharmaceutical and biotechnology industries, including the gene therapy and gene editing fields, are characterized by rapidly advancing…View ↗
Loading...
